← Leaderboards
John L Thompson
Columbia University Health Sciences
$26,060,206
Attributed
$29,254,384
Total exposure
11
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–22$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$30,589,713 · 11
FDA$1,974,822 · 1
By mechanism
U01$21,297,693 · 1
U54$6,620,302 · 7
R01$4,358,962 · 3
P30$287,578 · 1
Top collaborators
- Salvatore Dimauro20 shared
- Michio Hirano12 shared
- Peter W. Stacpoole4 shared
- Richard H Haas3 shared
- Russell P. Saneto3 shared
- Juan M. Pascual2 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Michio Hirano$20,704,569
- Salvatore Dimauro$5,976,336
- Arthur G. Palmer$45,042,966
- Eduardo Bonilla$2,069,157
- Dikoma C. Shungu$12,054,848
Others in their field
Top investigators on “Mitochondria”
- Bruce M Spiegelman · Dana-Farber Cancer Inst$30,163,696
- Shi Du Yan · Columbia University Health Sciences$29,685,201
- Peipei Ping · University Of California Los Angeles$27,344,561
- Mary McGrae McDermott · Northwestern University$25,752,019
- Vamsi Krishna Mootha · Massachusetts General Hospital$23,004,991
- Kenneth D. Tew · Fox Chase Cancer Center$22,000,362
Research focus
MitochondriaClinical TrialsAmericanMitochondrial DiseasesDesignData ManagementSiteResearch PersonnelSafetyCessation Of LifeRandomizedFundingMeetingsProgramsSyndromeEnsureEquilibriumGenesRare DiseasesBaseDisease-Causing MutationReportingMitochondrial DnaMutation
Grant awards (44)
Phase 3 Trial of DCA in PDC Deficiency IND 028,625 (02/04/2015)$496,401
R01 · FY2022 · FD
Phase 3 Trial of DCA in PDC Deficiency IND 028,625 (02/04/2015)$492,395
R01 · FY2021 · FD
Phase 3 Trial of DCA in PDC Deficiency IND 028,625 (02/04/2015)$494,425
R01 · FY2018 · FD
Phase 3 Trial of DCA in PDC Deficiency IND 028,625 (02/04/2015)$491,601
R01 · FY2016 · FD
North American Mitochondrial Disease Consortium (NAMDC)$1,085,410
U54 · FY2013 · NS
Adminitrative Unit$544,183
U54 · FY2013 · NS
AHSCT for MNGIE International Collaborative Trial (AMICT)$182,381
U54 · FY2013 · NS
Natural History of MNGIE (NAHIM)$147,112
U54 · FY2013 · NS
NAMDC Training$138,304
U54 · FY2013 · NS
Nautral History of Alpers Syndrome$73,430
U54 · FY2013 · NS
North American Mitochondrial Disease Consortium (NAMDC)$1,113,044
U54 · FY2012 · NS
Adminitrative Unit$504,657
U54 · FY2012 · NS
AHSCT for MNGIE International Collaborative Trial (AMICT)$184,727
U54 · FY2012 · NS
Natural History of MNGIE (NAHIM)$152,247
U54 · FY2012 · NS
NAMDC Training$145,594
U54 · FY2012 · NS
Nautral History of Alpers Syndrome$76,480
U54 · FY2012 · NS
NMR obervation of muscle and brain oxidative metabolism$49,339
U54 · FY2012 · NS
North American Mitochondrial Disease Consortium (NAMDC)$1,111,697
U54 · FY2011 · NS
Adminitrative Unit$450,418
U54 · FY2011 · NS
AHSCT for MNGIE International Collaborative Trial (AMICT)$190,359
U54 · FY2011 · NS
NAMDC Training$162,152
U54 · FY2011 · NS
Natural History of MNGIE (NAHIM)$152,079
U54 · FY2011 · NS
Nautral History of Alpers Syndrome$91,689
U54 · FY2011 · NS
NMR obervation of muscle and brain oxidative metabolism$65,000
U54 · FY2011 · NS
Warfarin vs Aspirin in Reduced Ejection Fraction - STAT$1,000,000
U01 · FY2010 · NS · contact PI
Warfarin vs Aspirin in Reduced Ejection Fraction - STAT$5,534,164
U01 · FY2009 · NS · contact PI
Phase IIB Study of TNK in Acute Stroke (TNK-S2B-STAT)$141,150
R01 · FY2009 · NS · contact PI
Warfarin vs Aspirin in Reduced Ejection Fraction - STAT$2,168,405
U01 · FY2008 · NS · contact PI
Warfarin vs Aspirin in Reduced Ejection Fraction - STAT$2,607,698
U01 · FY2007 · NS · contact PI
Biostatistics and Data Management Core$287,578
P30 · FY2007 · ES · contact PI
Warfarin vs Aspirin in Reduced Ejection Fraction -STAT$200,000
U01 · FY2007 · NS · contact PI
Clinical Trial of High Dose CoQ10 in ALS-QALS-=STAT$155,028
R01 · FY2007 · NS · contact PI
Phase IIB Study of TNK in Acute Stroke (TNK-S2B-STAT)$128,471
R01 · FY2007 · NS · contact PI
Warfarin vs Aspirin in Reduced Ejection Fraction -STAT$1,995,081
U01 · FY2006 · NS · contact PI
Clinical Trial of High Dose CoQ10 in ALS-QALS-=STAT$279,402
R01 · FY2006 · NS · contact PI
Phase IIB Study of TNK in Acute Stroke (TNK-S2B-STAT)$150,886
R01 · FY2006 · NS · contact PI
Warfarin vs Aspirin in Reduced Ejection Fraction -STAT$2,081,306
U01 · FY2005 · NS
Phase IIB Study of TNK in Acute Stroke (TNK-S2B-STAT)$479,068
R01 · FY2005 · NS
Clinical Trial of High Dose CoQ10 in ALS-QALS-=STAT$245,250
R01 · FY2005 · NS
Warfarin vs Aspirin in Reduced Ejection Fraction -STAT$2,043,118
U01 · FY2004 · NS
Phase IIB Study of TNK in Acute Stroke (TNK-S2B-STAT)$518,760
R01 · FY2004 · NS
Clinical Trial of High Dose CoQ10 in ALS-QALS-=STAT$286,125
R01 · FY2004 · NS
Warfarin vs Aspirin in Reduced Ejection Fraction -STAT$1,982,994
U01 · FY2002 · NS
Warfarin vs Aspirin in Reduced Ejection Fraction -STAT$1,684,927
U01 · FY2001 · NS